« Back
Home /
Elesclomol

Elesclomol

Item no.	HY-12040-10mg
Manufacturer	MedChem Express
CASRN	488832-69-5
Amount	10 mg
Quantity options	100 mg 10 mM/1 mL 10 mg 50 mg 5 mg
Category	Oncology Neuroscience Neuroinflammation Protein Aggregation, Clearance & Misfolding Inhibitors & Compound Libraries Small Molecules By Organ Lung Cancer Breast Cancer Lymphatic System Cancer
Type	Inhibitors
Specific against	other
Purity	99.80
Citations	[1]Kirshner JR, et al. Elesclomol induces cancer cell apoptosis through oxidative stress. Mol Cancer Ther. 2008 Aug;7(8):2319-27.\|[2]Bair JS, et al. Chemistry and biology of deoxynyboquinone, a potent inducer of cancer cell death. J Am Chem Soc. 2010 Apr 21;132(15):5469-7\|[3]Liam M Guthrie, et al. Elesclomol alleviates Menkes pathology and mortality by escorting Cu to cuproenzymes in mice. Science. 2020 May 8;368(6491):620-625.\|[4]Peter Tsvetkov, et al. Copper induces cell death by targeting lipoylated TCA cycle proteins. Science. 2022 Mar 18;375(6586):1254-1261.\|[5]Peter Tsvetkov, et al. Mitochondrial metabolism promotes adaptation to proteotoxic stress. Nat Chem Biol. 2019 Jul;15(7):681-689.
Smiles	S=C(C1=CC=CC=C1)N(NC(CC(NN(C(C2=CC=CC=C2)=S)C)=O)=O)C
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	STA-4783
Shipping Condition	Room temperature
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	Cancer-programmed cell death
Manufacturer - Targets	Apoptosis; Cuproptosis; Reactive Oxygen Species (ROS)
Shipping Temperature	Room Temperature
Storage Conditions	-20°C, 3 years; 4°C, 2 years (Powder)
Molecular Weight	400.5177
Product Description	Elesclomol (STA-4783) is a potent copper ionophore and promotes copper-dependent cell death (cuproptosis). Elesclomol specifically binds ferredoxin 1 (FDX1) α2/α3 helices and β5 strand. Elesclomol inhibits FDX1-mediated Fe-S cluster biosynthesis. Elesclomol is an oxidative stress inducer that induces cancer cell apoptosis. Elesclomol is a reactive oxygen species (ROS) inducer. Elesclomol can be used for Menkes and associated disorders of hereditary copper deficiency research[1][2][3][4].
Manufacturer - Research Area	Cancer
Solubility	DMSO: 100 mg/mL (ultrasonic)
Manufacturer - Pathway	Apoptosis; Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB
Clinical information	Phase 3

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-12040-10mg-safety-datasheet.pdf